• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·PRE
Share

Prenetics Global Limited Stocks

$ 21.63Last Updated 12.06.2026

Issuer Rating

3/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 367.72M

$ 21.63
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PRE is 31 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.06.2026 21:00

SpaceX debuts, OpenAI is one step closer to the stock exchange: highlights of the IPO by June 14

14.06.2026 18:01

ECB has raised rates, next move is for the Fed: what will be Kevin Warsh's first decision

14.06.2026 15:01

"A premium for candor": how top executives' comments affect companies' share prices

13.06.2026 22:31

U.S. and Iran to sign agreement on June 14, Strait of Hormuz to reopen - Trump

13.06.2026 16:01

Small caps last week: Record biotech IPO, Wizz Air's solid top line, SpaceX effect

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026